Obesity is associated with UTI and pyelonephritis

Study made in 5-year period (2002-2006)claimed that obesity is associated with UTI and pyelonephritis.A total of 95,598 subjects were identified for evaluation. Gender distribution was 42.9% male and 57.1% female. In the overall study cohort, the diagnosis of a UTI or pyelonephritis occurred in 13% and 0.84%, respectively. Women were 4.2 times more likely to be diagnosed with a UTI (19.3% vs 4.6%), and 3.6 times more likely to be diagnosed with pyelonephritis (1.22% vs 0.34%), than were men. At all stratifications of obesity, the obese were significantly more likely to be diagnosed with a UTI or pyelonephritis than nonobese patients.

For details contact at our email

Role of selenium in autoimmune thyroid disease

Autoimmune thyroid disease is gradually increasing globally. Studies conducted in the past 10 years have discovered role of selenium in the human health. Mortality , poor immune function , cognitive decline are seen with low levels while high levels are associated with antiviral effects, human reproduction and reduced risk of autoimmune thyroid disease. Supplementation of selenium above the normal reference range increases the risk of diabetes mellitus type II.

For details contact at our email.

TAK- 875 is better than glimepiride in management of Type 2 diabetes mellitus

Activation of free fatty acid receptor 1 (FFAR1; also known as G-protein-coupled receptor 40) by fatty acids stimulated glucose-dependent β-cell insulin secretion in preclinical models. Study was carried out to assess whether selective pharmacological activation of this receptor by TAK-875 in patients with type 2 diabetes mellitus improved glycaemic control without hypoglycaemia risk.

Its result was TAK-875 significantly improved glycaemic control in patients with type 2 diabetes with minimum risk of hypoglycaemia. The results show that activation of FFAR1 is a viable therapeutic target for treatment of type 2 diabetes.Based on the randomised double blind controlled trial conducted between Nov 17, 2009, and Sept 29, 2010, at 95 sites in the USA, Mexico, and Guatemala.

for full article email us at mteverestnp@gmail.com